Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexCelebrex safety has been called into question as a result of clinical trial findings regarding Celebrex and all COX-2 selective NSAIDs. Celebrex was first approved by the FDA in 1999 to treat the pain associated with osteoarthritis, rheumatoid arthritis, menstrual cramps, and other chronic pain conditions. Celebrex is also the only COX-2 selective pain killer which has been approved to treat adenomatous polyposis. Prior to concerns about Celebrex safety, this blockbuster painkiller was the tenth most popular drug on the market, bringing in almost three billion dollars in sales revenue each year.
Celebrex safety was first seriously questioned after a similar drug was pulled off the market in September 2004. Vioxx was voluntarily pulled off the market by Merck and Co. after they discovered that their painkiller doubled a patient’s risk of suffering serious adverse heart and stoke side effects. Since the Vioxx recall, Celebrex safety and the safety of all COX-2 selective NSAIDs has come under scrutiny.
Concerns about Celebrex safety mounted after a clinical trial was halted in late 2004. A three year Celebrex clinical trial was designed by the National Cancer Institute in order to test the efficiency of Celebrex at preventing the formation of colon polyps. This study was stopped short after preliminary evidence showed a significant lack in Celebrex safety. Patients who were taking 400 milligrams of Celebrex each day were 2.5 times more likely to suffer a heart attack or stroke compared to the control group population. Patients who were taking 800 milligrams of Celebrex were 3.4 times more likely to suffer a serious adverse cardiovascular or cerebrovascular event.
On December 17, 2004 Pfizer announced the results of this clinical trial and stated their intentions to evaluate Celebrex safety in greater detail. The pharmaceutical giant made no indication that they planned to pull Celebrex off the market, despite evidence of serious Celebrex dangers.
Since the release of this information, Celebrex safety concerns have prompted many doctors nationwide to halt similar studies, to urge doctors to stop prescribing this medication, and to encourage patients to seek safer alternative pain treatments. The FDA urged the medical community to limit the use of Celebrex until Celebrex safety could be better evaluated. The FDA publicly announced that Pfizer overstated the benefits and underestimated the risks of Celebrex use in their marketing materials. As a result, Pfizer was also ordered to pull all commercial advertisements for Celebrex until further notice.
Immediately after these Celebrex risks were discovered, the FDA initiated plans to further evaluate Celebrex safety and the safety of all COX-2 pain killers. In light of serious Celebrex safety concerns, class action and individual lawsuits have been filed against Pfizer all over the nation. If you are concerned about Celebrex safety, you may wish to contact your health care provider to discuss your concerns in greater detail.
If you or a loved one has been injured while taking Celebrex, you may wish to contact a qualified attorney who can help determine your legal rights and options in a case to seek relief for your losses.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...